31
total announcements
524632.BO · 15 min delayed
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has changed its name to Shukra Medtech Ltd, as approved by the Ministry of Corporate Affairs (MCA). The company is in the process of updating its records with the stock exchanges.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has issued a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of share certificates for the quarter ended September 30, 2026.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has allotted 17,35,000 fully paid-up equity shares to its promoters upon conversion of warrants, increasing the company's paid-up equity capital.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd provided a clarification on the significant movement in its share price, stating that it is fully compliant with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and that there is no undisclosed, price-sensitive information or any impending announcement/corporate event that needs to be shared with investors at this stage.
Shukra Pharmaceuticals Ltd
The BSE has sought clarification from Shukra Pharmaceuticals Ltd regarding significant price movement, to ensure investors have relevant information and safeguard their interests.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced the voting results of its postal ballot, with two resolutions passed. The first resolution amends the company's object clause, and the second resolution changes the company's name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced the voting results and scrutinizer's report for its 33rd Annual General Meeting (AGM), which was held on September 28, 2026. The meeting saw the passing of four resolutions, including the consideration and adoption of the audited financial statements for the financial year ended March 31, 2026, and the re-appointment of a director.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd held its 33rd Annual General Meeting (AGM) on September 28, 2026, through video conferencing. The meeting was chaired by Mr. Dhruvin Shah, Executive Director, and the Company Secretary confirmed the presence of the requisite quorum. The meeting was conducted in accordance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India. The Company Secretary informed the members about the general instructions regarding participation in the meeting and the facility for appointment of proxies was not applicable. The members were provided an option to vote through electronic mode, and the remote e-voting process was scrutinized by Mrs. Rupal Patel, Practicing Company Secretaries.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced the closure of its trading window for dealing in its securities from October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ended September 30, 2026.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd published a newspaper advertisement regarding a corrigendum to the postal ballot notice and information in terms of Section 108 of the Companies Act, 2013. The company secretary and compliance officer, Shivkant Dhakad, requested any person having or claiming any objection to intimate in writing with all necessary and supporting documents within 7 days from the date of publication.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has issued a corrigendum to its postal ballot notice dated August 22, 2026, to substitute the original independent auditor's certificate with a revised one, following observations from BSE Limited.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced its Annual Report 2025-26, including notice of AGM, audited financial statements, and resolutions for final dividend, re-appointment of director, and regularization of additional independent director.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced the notice of its 33rd Annual General Meeting (AGM) to be held on September 28, 2026, through video conferencing. The meeting will consider the adoption of audited financial statements for the year ended March 31, 2026, declaration of a final dividend, re-appointment of a director, and regularization of an additional independent director.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has rescheduled its 33rd Annual General Meeting (AGM) to September 28, 2026, due to unavoidable administrative exigencies. The revised book closure dates are September 22-28, 2026.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced the record date for determining eligibility for the final dividend of 0.01 per equity share for the financial year ended 31 March 2026, subject to approval at the 33rd Annual General Meeting.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has allotted 11,73,000 fully paid-up equity shares of Re.1/- each to Navkar Surgical Gujarat Limited, warrant holders (Promoter), upon conversion of warrants into equity shares. The allotment has been made for cash, upon receipt of the remaining exercise price of Rs.26.67/- per share warrant, aggregating to Rs.3,12,83,910/-.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has published a newspaper advertisement for the completion of dispatch of the postal Ballot Notice as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has issued a postal ballot notice for shareholders to approve a resolution to amend the object clause of the Memorandum of Association of the Company. The e-voting period will commence on August 28, 2026, and end on September 26, 2026. The result of the voting will be announced not later than two working days or three days from the conclusion of the e-voting.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has held a board meeting where they approved a change in the company's name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited', subject to approval from shareholders and relevant regulatory bodies. The company also approved the alteration in the main objects of the Company and consequential Alteration in the Main Object Clause of the Memorandum of Association. The 33rd Annual General Meeting (AGM) of the shareholders will be held on September 25, 2026, through video conferencing.
Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals Ltd has announced that it has been listed on the National Stock Exchange of India Limited (NSE) and is now available for trading on both BSE Limited and NSE. The company's strategic direction focuses on Medical Technology, Artificial Intelligence, healthcare innovation, and technology-enabled healthcare solutions.